Literature DB >> 33709973

Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis.

Finja Schweitzer1, Nina N Kleineberg1,2, Yasemin Göreci1, Oezguer A Onur1,2, Christiana Franke3, Clemens Warnke1.   

Abstract

PURPOSE OF REVIEW: To provide an overview on current knowledge of neurological symptoms and complications of COVID-19, and to suggest management concepts. RECENT
FINDINGS: Headache, dizziness, excessive tiredness, myalgia, anosmia/hyposmia, and ageusia/dysgeusia are common nonspecific neurological manifestations during early COVID-19 disease found in the majority of patients. Less frequent but more severe and specific neurological manifestations include Guillain--Barré syndrome, encephalopathy, encephalitis/meningitis, epileptic seizures, and cerebrovascular events. Beyond standard neurological examination, these require a more extensive work-up, including cerebrospinal fluid assessment, neurophysiological evaluation, neuroimaging, and cognitive testing. Symptomatic treatment is advisable unless the neurological complication's immune pathogenesis is proven.
SUMMARY: Neurological manifestations of COVID-19 occur during the acute, para-infectious, and 'recovery' phase. Therapeutic management depends on the clinical presentation and neurological work-up.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33709973     DOI: 10.1097/WCO.0000000000000930

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  8 in total

1.  Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS).

Authors:  Nina N Kleineberg; Samuel Knauss; Eileen Gülke; Hans O Pinnschmidt; Carolin E M Jakob; Paul Lingor; Kerstin Hellwig; Achim Berthele; Günter Höglinger; Gereon R Fink; Matthias Endres; Christian Gerloff; Christine Klein; Melanie Stecher; Annika Y Classen; Siegbert Rieg; Stefan Borgmann; Frank Hanses; Maria M Rüthrich; Martin Hower; Lukas Tometten; Martina Haselberger; Christiane Piepel; Uta Merle; Sebastian Dolff; Christian Degenhardt; Björn-Erik O Jensen; Maria J G T Vehreschild; Johanna Erber; Christiana Franke; Clemens Warnke
Journal:  Eur J Neurol       Date:  2021-09-03       Impact factor: 6.288

2.  Do the Successive Waves of SARS-CoV-2, Vaccination Status and Place of Infection Influence the Clinical Picture and COVID-19 Severity among Patients with Persistent Clinical Symptoms? The Retrospective Study of Patients from the STOP-COVID Registry of the PoLoCOV-Study.

Authors:  Michał Chudzik; Mateusz Babicki; Joanna Kapusta; Damian Kołat; Żaneta Kałuzińska; Agnieszka Mastalerz-Migas; Piotr Jankowski
Journal:  J Pers Med       Date:  2022-04-28

3.  Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020.

Authors:  Antonio L Teixeira; Trudy Millard Krause; Lopita Ghosh; Lokesh Shahani; Rodrigo Machado-Vieira; Scott D Lane; Eric Boerwinkle; Jair C Soares
Journal:  JAMA Netw Open       Date:  2021-11-01

Review 4.  Neurological sequelae of COVID-19: a review.

Authors:  Christopher J Peterson; Ashish Sarangi; Fariha Bangash
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2021-09-08

Review 5.  Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation.

Authors:  Anthony J Turner; Natalia N Nalivaeva
Journal:  Peptides       Date:  2022-02-10       Impact factor: 3.750

Review 6.  [Manifestations of the central nervous system after COVID-19].

Authors:  Ameli Gerhard; Harald Prüß; Christiana Franke
Journal:  Nervenarzt       Date:  2022-05-12       Impact factor: 1.297

7.  Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients.

Authors:  Anna Lisa Martini; Giulia Carli; Lorenzo Kiferle; Patrizia Piersanti; Pasquale Palumbo; Silvia Morbelli; Maria Lucia Calcagni; Daniela Perani; Stelvio Sestini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-19       Impact factor: 10.057

8.  Cerebrospinal Fluid Analysis Post-COVID-19 Is Not Suggestive of Persistent Central Nervous System Infection.

Authors:  Finja Schweitzer; Yasemin Goereci; Veronica Di Cristanziano; Clemens Warnke; Christiana Franke; Steffi Silling; Fabian Bösl; Franziska Maier; Eva Heger; Birgit Deiman; Harald Prüss; Oezguer A Onur; Florian Klein; Gereon R Fink
Journal:  Ann Neurol       Date:  2021-11-22       Impact factor: 11.274

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.